Market News AIOpen the app

Vanda Pharmaceuticals has signed a deal to settle a patent dispute, letting MSN sell a generic version of HETLIOZ LQ.

DealRead the original at SEC EDGAR
Good for VNDA

Vanda's deal sets MSN's generic market entry for Q1 2040, with earlier entry possible in listed cases. The delay favors Vanda, though MSN gets a royalty-free license and could enter sooner under those conditions.

VNDA · Vanda Pharmaceuticals Inc.

AI read · Good for VNDA

The AI's read

This gives Vanda a long delay before this generic can compete, and MSN recognizes the patents for its product. The planned court order would bar sales without Vanda's license, but still needs court approval. Vanda grants a royalty-free license, and listed conditions could allow earlier entry. The delay and patent recognition make the deal favorable despite those limits.

Get alerts for VNDA

Follow Vanda Pharmaceuticals Inc. (VNDA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VNDA
Free on the App Store and Google Play, or on the web.